MD3226841T2 - Compoziții anticancerigene - Google Patents

Compoziții anticancerigene

Info

Publication number
MD3226841T2
MD3226841T2 MDE20170152T MDE20170152T MD3226841T2 MD 3226841 T2 MD3226841 T2 MD 3226841T2 MD E20170152 T MDE20170152 T MD E20170152T MD E20170152 T MDE20170152 T MD E20170152T MD 3226841 T2 MD3226841 T2 MD 3226841T2
Authority
MD
Moldova
Prior art keywords
hpmcas
solid dispersion
arn
rna
formulation
Prior art date
Application number
MDE20170152T
Other languages
English (en)
Romanian (ro)
Inventor
Dennis Martin Hester
Jason Michael Vaughn
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3226841(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of MD3226841T2 publication Critical patent/MD3226841T2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MDE20170152T 2014-12-05 2015-12-03 Compoziții anticancerigene MD3226841T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14196594 2014-12-05
PCT/US2015/063661 WO2016090098A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Publications (1)

Publication Number Publication Date
MD3226841T2 true MD3226841T2 (ro) 2025-06-30

Family

ID=52006906

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20170152T MD3226841T2 (ro) 2014-12-05 2015-12-03 Compoziții anticancerigene

Country Status (29)

Country Link
US (3) US20170360754A1 (OSRAM)
EP (2) EP3226841B1 (OSRAM)
JP (2) JP6937692B2 (OSRAM)
KR (2) KR20200141533A (OSRAM)
CN (2) CN114886852A (OSRAM)
AR (1) AR102926A1 (OSRAM)
AU (3) AU2015358490B2 (OSRAM)
BR (1) BR112017011788A2 (OSRAM)
CA (1) CA2969656A1 (OSRAM)
CL (1) CL2017001371A1 (OSRAM)
CO (1) CO2017005572A2 (OSRAM)
CR (1) CR20170216A (OSRAM)
EA (1) EA201791222A1 (OSRAM)
ES (1) ES2996833T3 (OSRAM)
HR (1) HRP20241719T1 (OSRAM)
HU (1) HUE069689T2 (OSRAM)
IL (2) IL252323B (OSRAM)
MA (1) MA41107B1 (OSRAM)
MD (1) MD3226841T2 (OSRAM)
MX (2) MX387933B (OSRAM)
NZ (1) NZ770528A (OSRAM)
PH (1) PH12017500964A1 (OSRAM)
PL (1) PL3226841T3 (OSRAM)
RS (1) RS66323B1 (OSRAM)
SG (1) SG11201704267VA (OSRAM)
SM (1) SMT202400518T1 (OSRAM)
TW (2) TWI702966B (OSRAM)
UA (1) UA120950C2 (OSRAM)
WO (1) WO2016090098A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
PT3226843T (pt) 2014-12-05 2021-07-07 Aragon Pharmaceuticals Inc Composições anticancro
KR20200141533A (ko) 2014-12-05 2020-12-18 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
WO2020144646A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Apalutamide dispersed in applesauce for treating prostate cancer
EP3917519A1 (en) 2019-01-30 2021-12-08 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
JP2022524289A (ja) 2019-01-30 2022-05-02 ヤンセン ファーマシューティカ エヌ．ベー． 分子サブタイプに基づいて前立腺癌を治療する方法
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide
US11723898B2 (en) 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en) 2020-09-04 2022-03-10 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023122842A1 (es) * 2021-12-31 2023-07-06 Gador Limitada Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
CN116183787A (zh) * 2022-12-26 2023-05-30 郑州德迈药业有限公司 醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法
TW202444354A (zh) 2023-03-16 2024-11-16 瑞士商拜耳保健消費品股份有限公司 用於治療荷爾蒙敏感性前列腺癌生化復發患者之雄激素受體拮抗劑
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide
WO2025174375A1 (en) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69327096T2 (de) 1992-03-31 2000-06-21 Btg International Ltd., London 17-substituierte steroide, verwendbar bei behandlung von krebs
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
WO2001060410A1 (en) 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
US20040067257A1 (en) 2001-02-27 2004-04-08 Nicola Bateman Pharmaceutical formulation
SK12032003A3 (sk) 2001-04-02 2004-03-02 Astrazeneca Ab Farmaceutická formulácia obsahujúca 4'-kyano-alfa', alfa', alfa'-trifluór-3-(4-fluórfenylsulfonyl)-2-hydroxy-2- metylpropiono-m-toluidín a PVP
WO2003000292A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
AU2003239463B2 (en) * 2002-02-01 2007-10-18 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
JPWO2003077827A1 (ja) 2002-03-19 2005-07-14 日本新薬株式会社 医薬固体分散体の製造方法
JP2007518670A (ja) 2003-12-15 2007-07-12 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 苦味のある薬物、及びｐＨ感受性ポリマーを含む風味マスクされた医薬組成物
GB0502790D0 (en) 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
KR102481886B1 (ko) 2005-05-13 2022-12-28 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
KR101819199B1 (ko) 2010-02-16 2018-01-16 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제 및 이의 용도
CN102525876B (zh) 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
EP2721003B1 (en) 2011-06-15 2018-01-03 The United States of America, as Represented by The Secretary, Department of Health and Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en) 2012-03-21 2015-02-05 Emphascience, Inc. Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
CA3008345C (en) 2012-06-07 2019-10-22 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
MX2015002430A (es) * 2012-08-24 2015-06-22 Dow Global Technologies Llc Acetato-succinatos de hidroxialquilmetilcelulosa.
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence
CN105358535B (zh) * 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
EA030128B1 (ru) * 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
PE20151335A1 (es) 2013-01-22 2015-09-18 Hoffmann La Roche Composicion farmaceutica con biodisponibilidad mejorada
KR20180021932A (ko) 2013-03-15 2018-03-05 아이슈티카 인코포레이티드 아비라테론 아세테이트 제제
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CA2920317A1 (en) * 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
WO2015118015A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途
KR20200141533A (ko) 2014-12-05 2020-12-18 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
ES3021508T3 (en) 2014-12-05 2025-05-27 Aragon Pharmaceuticals Inc Anticancer compositions
PT3226843T (pt) 2014-12-05 2021-07-07 Aragon Pharmaceuticals Inc Composições anticancro
MA45090A (fr) 2016-06-03 2021-04-28 Aragon Pharmaceuticals Inc Compositions anticancéreuses
EP3812378A4 (en) 2018-06-20 2021-04-28 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORMS OF RNA-509, CORRESPONDING METHOD OF PREPARATION AND ASSOCIATED USE
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide

Also Published As

Publication number Publication date
MA41107B1 (fr) 2025-01-31
IL252323B (en) 2021-04-29
HUE069689T2 (hu) 2025-04-28
TWI754258B (zh) 2022-02-01
PH12017500964A1 (en) 2017-10-18
AU2023202710A1 (en) 2023-05-18
CN106999431B (zh) 2022-03-04
EP3226841A1 (en) 2017-10-11
ES2996833T3 (en) 2025-02-13
CA2969656A1 (en) 2016-06-09
AU2021201979A1 (en) 2021-04-29
IL279833B (en) 2022-03-01
SMT202400518T1 (it) 2025-01-14
RS66323B1 (sr) 2025-01-31
TWI702966B (zh) 2020-09-01
MX387933B (es) 2025-03-19
MX2021013965A (es) 2022-01-04
MA41107A (fr) 2017-10-10
KR102348320B1 (ko) 2022-01-10
EP3226841B1 (en) 2024-10-09
NZ770528A (en) 2024-03-22
WO2016090098A1 (en) 2016-06-09
JP6937692B2 (ja) 2021-09-22
PL3226841T3 (pl) 2025-03-03
US20170360754A1 (en) 2017-12-21
NZ731963A (en) 2024-03-22
HRP20241719T1 (hr) 2025-02-14
TW202031248A (zh) 2020-09-01
IL279833A (en) 2021-01-31
US20240293374A1 (en) 2024-09-05
KR20170086656A (ko) 2017-07-26
KR20200141533A (ko) 2020-12-18
US12303493B2 (en) 2025-05-20
JP2020143069A (ja) 2020-09-10
CN114886852A (zh) 2022-08-12
BR112017011788A2 (pt) 2017-12-26
UA120950C2 (uk) 2020-03-10
TW201630592A (zh) 2016-09-01
AR102926A1 (es) 2017-04-05
CN106999431A (zh) 2017-08-01
SG11201704267VA (en) 2017-06-29
EP4494636A3 (en) 2025-04-30
EP4494636A2 (en) 2025-01-22
AU2015358490A1 (en) 2017-06-08
US20230233529A1 (en) 2023-07-27
AU2015358490B2 (en) 2021-04-08
CO2017005572A2 (es) 2017-09-20
JP2017536398A (ja) 2017-12-07
AU2021201979B2 (en) 2023-02-02
EA201791222A1 (ru) 2017-09-29
MX2017007203A (es) 2017-08-28
EP3226841C0 (en) 2024-10-09
CL2017001371A1 (es) 2018-01-05
CR20170216A (es) 2017-08-30
JP7174006B2 (ja) 2022-11-17
IL252323A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
US12303493B2 (en) Anticancer compositions
US20240293321A1 (en) Anticancer compositions
HK40078336A (en) Anticancer compositions
HK1241764A1 (en) Anticancer compositions
HK1241764B (en) Anticancer compositions
EA043321B1 (ru) Противораковая композиция
HK1241758A1 (en) Anticancer compositions